$MDGL
Madrigal Pharmaceuticals Inc Stock $mdgl

$mdgl Overview Financials Valuation SEC Filings Company Website

2012 Q4 Form 10-Q Financial Statement

#000110465912074384 Filed on November 06, 2012

Income Statement

Concept	2012 Q4	2012 Q3	2011 Q3
Revenue	$0.00	$0.00	$521.0K
YoY Change	-100.0%	-100.0%	-84.68%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.400M	$2.800M	$3.100M
YoY Change	21.43%	-9.68%	19.23%
% of Gross Profit
Research & Development	$14.35M	$11.74M	$10.75M
YoY Change	32.16%	9.23%	-2.47%
% of Gross Profit
Depreciation & Amortization	$120.0K	$200.0K	$400.0K
YoY Change	-58.62%	-50.0%	-14.89%
% of Gross Profit
Operating Expenses	$17.70M	$14.54M	$13.88M
YoY Change	29.58%	4.73%	1.97%
Operating Profit	-$17.70M	-$14.54M	-$12.22M
YoY Change	72.9%	19.0%	19.42%
Interest Expense	-$420.0K	-$457.0K	-$516.0K
YoY Change	-16.67%	-11.43%	1564.52%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$18.10M	-$15.00M	-$12.70M
YoY Change	69.16%	18.11%	23.3%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$18.10M	-$15.00M	-$12.70M
YoY Change	69.16%	18.11%	23.3%
Net Earnings / Revenue			-2437.62%
Basic Earnings Per Share
Diluted Earnings Per Share	-$10.06M	-$8.824M	-$9.071M
COMMON SHARES
Basic Shares Outstanding	61.90M shares		49.50M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2012 Q4	2012 Q3	2011 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$100.6M	$55.10M	$50.70M
YoY Change	153.4%	8.68%	-6.28%
Cash & Equivalents	$81.51M	$29.44M	$20.60M
Short-Term Investments	$19.10M	$25.70M	$30.00M
Other Short-Term Assets	$800.0K	$800.0K	$1.400M
YoY Change	33.33%	-42.86%	100.0%
Inventory
Prepaid Expenses
Receivables			$0.00
Other Receivables			$0.00
Total Short-Term Assets	$101.4M	$55.90M	$52.02M
YoY Change	151.66%	7.45%	-5.07%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.174M	$1.205M	$1.300M
YoY Change	-16.56%	-7.31%	-50.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$458.0K	$466.0K	$500.0K
YoY Change	-27.42%	-6.8%	0.0%
Total Long-Term Assets	$1.632M	$1.713M	$1.846M
YoY Change	-19.92%	-7.2%	-40.45%
TOTAL ASSETS
Total Short-Term Assets	$101.4M	$55.90M	$52.02M
Total Long-Term Assets	$1.632M	$1.713M	$1.846M
Total Assets	$103.0M	$57.61M	$53.87M
YoY Change	143.4%	6.95%	-6.96%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.661M	$3.690M	$2.900M
YoY Change	63.28%	27.24%	20.83%
Accrued Expenses	$9.900M	$7.400M	$6.300M
YoY Change	33.78%	17.46%	5.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Long-Term Debt Due	$7.900M	$7.900M	$4.600M
YoY Change	88.1%	71.74%	1433.33%
Total Short-Term Liabilities	$23.49M	$18.97M	$17.12M
YoY Change	55.04%	10.8%	14.87%
LONG-TERM LIABILITIES
Long-Term Debt	$4.500M	$6.500M	$12.20M
YoY Change	-63.71%	-46.72%	-8.96%
Other Long-Term Liabilities			$0.00
YoY Change			-100.0%
Total Long-Term Liabilities	$4.465M	$6.458M	$12.17M
YoY Change	-64.0%	-46.94%	-27.12%
TOTAL LIABILITIES
Total Short-Term Liabilities	$23.49M	$18.97M	$17.12M
Total Long-Term Liabilities	$4.465M	$6.458M	$12.17M
Total Liabilities	$27.95M	$25.42M	$29.29M
YoY Change	1.46%	-13.19%	-7.32%
SHAREHOLDERS EQUITY
Retained Earnings	-$461.2M	-$443.1M
YoY Change	15.76%
Common Stock	$536.3M	$475.3M
YoY Change	29.79%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$75.07M	$32.19M	$24.60M
YoY Change
Total Liabilities & Shareholders Equity	$103.0M	$57.61M	$53.87M
YoY Change	143.4%	6.95%	-6.96%

Cashflow Statement

Concept	2012 Q4	2012 Q3	2011 Q3
OPERATING ACTIVITIES
Net Income	-$18.10M	-$15.00M	-$12.70M
YoY Change	69.16%	18.11%	23.3%
Depreciation, Depletion And Amortization	$120.0K	$200.0K	$400.0K
YoY Change	-58.62%	-50.0%	-14.89%
Cash From Operating Activities	-$12.53M	-$13.26M	-$11.82M
YoY Change	19.45%	12.18%	40.21%
INVESTING ACTIVITIES
Capital Expenditures	-$90.00K	-$210.0K	-$260.0K
YoY Change	-76.32%	-19.23%	271.43%
Acquisitions
YoY Change
Other Investing Activities	$6.600M	-$6.630M	$6.970M
YoY Change	-67.6%	-195.12%	-152.96%
Cash From Investing Activities	$6.520M	-$6.840M	$6.710M
YoY Change	-67.38%	-201.94%	-150.72%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	58.08M	23.95M	-130.0K
YoY Change	-83071.43%	-18523.08%	-100.93%
NET CHANGE
Cash From Operating Activities	-12.53M	-13.26M	-11.82M
Cash From Investing Activities	6.520M	-6.840M	6.710M
Cash From Financing Activities	58.08M	23.95M	-130.0K
Net Change In Cash	52.07M	3.850M	-5.240M
YoY Change	452.17%	-173.47%	-31.95%
FREE CASH FLOW
Cash From Operating Activities	-$12.53M	-$13.26M	-$11.82M
Capital Expenditures	-$90.00K	-$210.0K	-$260.0K
Free Cash Flow	-$12.44M	-$13.05M	-$11.56M
YoY Change	23.05%	12.89%	38.28%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	623000	USD
CY2012Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	200000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1173000	USD
CY2011Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	400000	USD
CY2012Q1	snta	Proceeds From Issuance Or Sale Of Equity Gross ProceedsFromIssuanceOrSaleOfEquityGross	35400000	USD
CY2012Q1	us-gaap	Share Price SharePrice	4.40
CY2012Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	7000000	shares
CY2012Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1050000	shares
CY2012Q1	snta	Stock Issued During Period Shares To Directors StockIssuedDuringPeriodSharesToDirectors	1136363	shares
CY2012Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	33000000	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.77
	dei	Entity Central Index Key EntityCentralIndexKey	0001157601
	dei	Document Type DocumentType	10-Q
	us-gaap	Nature Of Operations NatureOfOperations	<table style="font-size:10pt; font-family:'Times New Roman',times,serif;"> <tr> <td> <p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold" size="2">(1) Nature of Business</font></b></p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">Synta Pharmaceuticals Corp. (the Company) was incorporated in March 2000 and commenced operations in July 2001. The Company is a biopharmaceutical company focusing on discovering, developing and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases.</font></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">The Company is subject to risks common to emerging companies in the drug development and pharmaceutical industry including, but not limited to, uncertainty of product development and commercialization, lack of marketing and sales history, dependence on key personnel, uncertainty of market acceptance of products, product liability, uncertain protection of proprietary technology, potential inability to raise additional financing and compliance with the U.S. Food and Drug Administration and other government regulations.</font></p></td></tr></table>
	dei	Entity Registrant Name EntityRegistrantName	SYNTA PHARMACEUTICALS CORP
	dei	Document Period End Date DocumentPeriodEndDate	2012-09-30
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2012
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	us-gaap	Use Of Estimates UseOfEstimates	<table style="font-size:10pt; font-family:'Times New Roman',times,serif;"> <tr> <td> <p style="MARGIN: 0in 0in 0pt"> </p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Significant items subject to such estimates and assumptions include contract research accruals, recoverability of long-lived assets, measurement of stock-based compensation, and the periods of performance under its collaborative research and development agreements. The Company bases its estimates on historical experience and various other assumptions that management believes to be reasonable under the circumstances. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.</font></p></td></tr></table>
CY2011Q3	us-gaap	Revenue From Grants RevenueFromGrants	521000	USD
	us-gaap	Revenue From Grants RevenueFromGrants	732000	USD
	snta	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate	0.10	pure
CY2012	snta	Period Of Grant Received PeriodOfGrantReceived	P1Y
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	item
CY2012Q3	snta	Cash And Cash Equivalents And Available For Sale Securities Gross Unrealized Gains CashAndCashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGains	8000	USD
CY2012Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	29442000	USD
CY2011Q4	snta	Cash And Cash Equivalents And Available For Sale Securities Gross Unrealized Gains CashAndCashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGains	3000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	30075000	USD
CY2012Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2011Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	19358000	USD
CY2011Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1407000	USD
CY2012Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1205000	USD
CY2012Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	19981000	USD
CY2011Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	20765000	USD
CY2012Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	21186000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2359000	USD
CY2012Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	801000	USD
CY2011Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	867000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2506000	USD
CY2012Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	8583000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y8M16D
CY2012Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1979000	USD
CY2012Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	851000	USD
CY2012Q3	snta	Accrued Liabilities Current Excluding Accrued Contract Research Costs AccruedLiabilitiesCurrentExcludingAccruedContractResearchCosts	3643000	USD
CY2011Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2914000	USD
CY2011Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1069000	USD
CY2011Q4	snta	Accrued Liabilities Current Excluding Accrued Contract Research Costs AccruedLiabilitiesCurrentExcludingAccruedContractResearchCosts	4594000	USD
CY2012Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	1966000	USD
CY2012Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	7924000	USD
CY2012Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	4464000	USD
CY2012Q3	us-gaap	Secured Debt SecuredDebt	14354000	USD
CY2012	us-gaap	Revenue From Grants RevenueFromGrants	1000000	USD
CY2012Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	813000	USD
CY2011Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	611000	USD
CY2011Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	9650000	USD
CY2011Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	561000	USD
CY2011Q4	us-gaap	Assets Current AssetsCurrent	40286000	USD
CY2011Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	631000	USD
CY2011Q4	us-gaap	Assets Assets	42324000	USD
CY2012Q3	us-gaap	Assets Assets	57613000	USD
CY2011Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3467000	USD
CY2011Q4	snta	Accrued Contract Research Costs AccruedContractResearchCosts	2841000	USD
CY2011Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	12000	USD
CY2011Q4	us-gaap	Secured Debt Current SecuredDebtCurrent	4234000	USD
CY2011Q4	us-gaap	Liabilities Current LiabilitiesCurrent	15148000	USD
CY2012Q3	us-gaap	Liabilities Current LiabilitiesCurrent	18965000	USD
CY2011Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	14000	USD
CY2011Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	12388000	USD
CY2011Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	12402000	USD
CY2011Q4	us-gaap	Liabilities Liabilities	27550000	USD
CY2012Q3	us-gaap	Liabilities Liabilities	25423000	USD
CY2011Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2011Q4	us-gaap	Common Stock Value CommonStockValue	5000	USD
CY2011Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	413196000	USD
CY2011Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	3000	USD
CY2011Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-398430000	USD
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	14774000	USD
CY2011Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	42324000	USD
CY2012Q3	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2012Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	57613000	USD
CY2012Q3	us-gaap	Stockholders Equity StockholdersEquity	32190000	USD
CY2011Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2012Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2011Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2012Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2012Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2011Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2011Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2012Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2011Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2012Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2011Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2011Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	49539808	shares
CY2011Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	49539808	shares
CY2012Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	61881097	shares
CY2012Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	61881097	shares
CY2011Q3	snta	License And Milestone Revenues LicenseAndMilestoneRevenues	1143000	USD
	snta	License And Milestone Revenues LicenseAndMilestoneRevenues	3429000	USD
CY2011Q3	snta	Collaborative Revenues CollaborativeRevenues	1143000	USD
	snta	Collaborative Revenues CollaborativeRevenues	3429000	USD
CY2011Q3	snta	Total Revenues TotalRevenues	1664000	USD
	snta	Total Revenues TotalRevenues	4161000	USD
CY2011Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	10751000	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	30605000	USD
CY2011Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3131000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8749000	USD
CY2011Q3	us-gaap	Operating Expenses OperatingExpenses	13882000	USD
	us-gaap	Operating Expenses OperatingExpenses	39354000	USD
CY2011Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-12218000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-35193000	USD
CY2011Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-516000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-1444000	USD
CY2011Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-12734000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-36637000	USD
CY2011Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.26
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.79
	snta	Total Revenues TotalRevenues	147000	USD
CY2012Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-14996000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-10658000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-16463000	USD
	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	2000000	USD
CY2011Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12743000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-36633000	USD
CY2012Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-14992000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-44662000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2506000	USD
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-116000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	931000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	164000	USD
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	997000	USD
	snta	Increase Decrease Accrued Contract And Research Costs IncreaseDecreaseAccruedContractAndResearchCosts	499000	USD
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-945000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-3428000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-36814000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-41612000	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	46994000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	36644000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	308000	USD
	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	233000	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	190000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	36805000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	57442000	USD
	us-gaap	Interest Paid InterestPaid	1484000	USD
CY2011Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	49403589	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	46446328	shares
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-10667000	USD
CY2012Q3	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	25697000	USD
CY2012Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	803000	USD
CY2012Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	466000	USD
CY2012Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	3690000	USD
CY2012Q3	snta	Accrued Contract Research Costs AccruedContractResearchCosts	3719000	USD
CY2012Q3	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	13000	USD
CY2012Q3	us-gaap	Secured Debt Current SecuredDebtCurrent	7900000	USD
CY2012Q3	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	4000	USD
CY2012Q3	us-gaap	Secured Long Term Debt SecuredLongTermDebt	6454000	USD
CY2012Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	6458000	USD
CY2012Q3	us-gaap	Common Stock Value CommonStockValue	6000	USD
CY2012Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	475273000	USD
CY2012Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	8000	USD
CY2012Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-443097000	USD
	us-gaap	Revenue From Grants RevenueFromGrants	147000	USD
CY2012Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	11743000	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	35061000	USD
CY2012Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2796000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8324000	USD
CY2012Q3	us-gaap	Operating Expenses OperatingExpenses	14539000	USD
	us-gaap	Operating Expenses OperatingExpenses	43385000	USD
CY2012Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-14539000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-43238000	USD
CY2012Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-457000	USD
CY2012Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	60661720	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	58235263	shares
	us-gaap	Share Based Compensation ShareBasedCompensation	2359000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	242000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-165000	USD
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	223000	USD
	snta	Increase Decrease Accrued Contract And Research Costs IncreaseDecreaseAccruedContractAndResearchCosts	878000	USD
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-951000	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	45887000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-1429000	USD
CY2012Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.25
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	29845000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	421000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-633000	USD
	us-gaap	Interest Paid InterestPaid	1335000	USD
CY2011Q1	snta	Amount Of Grant Awarded AmountOfGrantAwarded	1000000	USD
CY2012Q1	snta	Aggregate Number Of Shares Sold AggregateNumberOfSharesSold	8050000	shares
CY2012Q1	us-gaap	Share Price SharePrice	4.40
CY2012Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	4000	USD
CY2011Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-9000	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	5000	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	4000	USD
CY2012Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	61900896	shares
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<table style="font-size:10pt; font-family:'Times New Roman',times,serif;"> <tr> <td> <p style="MARGIN: 0in 0in 0pt"> </p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"> </font></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">Certain amounts in prior years’ financial statements have been reclassified to conform to the current period presentation. The Company reclassified $7.7 million from proceeds from the issuance of common stock to proceeds from the issuance of common stock to related parties on the statement of cash flows for the nine months ended September 30, 2011. The reclassification had no effect on the Company’s previously reported consolidated balance sheet and results of operations as of and for the nine months ended September 30, 2011.</font></p></td></tr></table>
	snta	Proceeds From Issuance Of Common Stock To Related Parties ProceedsFromIssuanceOfCommonStockToRelatedParties	7734000	USD
	snta	Proceeds From Issuance Of Common Stock To Related Parties ProceedsFromIssuanceOfCommonStockToRelatedParties	30759000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	27494000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	28960000	USD
CY2012Q3	snta	Stock Issued During Period Shares To Directors In Registered Direct Offering StockIssuedDuringPeriodSharesToDirectorsInRegisteredDirectOffering	3976702	shares
CY2012Q3	us-gaap	Share Price SharePrice	6.49
CY2012Q3	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	25800000	USD
CY2012Q3	us-gaap	Availableforsale Securities Gross Unrealized Gain AvailableforsaleSecuritiesGrossUnrealizedGain	8000	USD
	snta	Number Of Months Recognize Deferred Amount As Revenue NumberOfMonthsRecognizeDeferredAmountAsRevenue	12	item
	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	2268000	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	9000	USD

Files In Submission

Name	View Source	Status
0001104659-12-074384-index-headers.html	Edgar Link	pending
0001104659-12-074384-index.html	Edgar Link	pending
0001104659-12-074384.txt	Edgar Link	pending
0001104659-12-074384-xbrl.zip	Edgar Link	pending
a12-20042_110q.htm	Edgar Link	pending
a12-20042_1ex31d1.htm	Edgar Link	pending
a12-20042_1ex31d2.htm	Edgar Link	pending
a12-20042_1ex32d1.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
g200421bii001.gif	Edgar Link	pending
g200421bki001.gif	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
snta-20120930.xml	Edgar Link	completed
snta-20120930.xsd	Edgar Link	pending
snta-20120930_cal.xml	Edgar Link	unprocessable
snta-20120930_def.xml	Edgar Link	unprocessable
snta-20120930_lab.xml	Edgar Link	unprocessable
snta-20120930_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MDGL
Madrigal Pharmaceuticals Inc Stock $mdgl

2012 Q4 Form 10-Q Financial Statement

#000110465912074384 Filed on November 06, 2012

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MDGL Madrigal Pharmaceuticals Inc Stock $mdgl

2012 Q4 Form 10-Q Financial Statement

#000110465912074384 Filed on November 06, 2012

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MDGL
Madrigal Pharmaceuticals Inc Stock $mdgl